{"nctId":"NCT03103152","briefTitle":"A Study to Examine the Effectiveness of Aspirin and/or Vitamin D3 to Prevent Prostate Cancer Progression","startDateStruct":{"date":"2016-12"},"conditions":["Prostate Cancer"],"count":104,"armGroups":[{"label":"High dose Aspirin & Vitamin D","type":"EXPERIMENTAL","interventionNames":["Drug: High dose Aspirin & Vitamin D"]},{"label":"High dose Aspirin, Vitamin D placebo","type":"EXPERIMENTAL","interventionNames":["Drug: High dose Aspirin, Vitamin D placebo","Drug: Aspirin placebo, Vitamin D placebo"]},{"label":"Low dose Aspirin , Vitamin D","type":"EXPERIMENTAL","interventionNames":["Drug: Low dose Aspirin , Vitamin D"]},{"label":"Low dose Aspirin, Vitamin D placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Low dose Aspirin, Vitamin D placebo"]},{"label":"Aspirin Placebo, Vitamin D","type":"EXPERIMENTAL","interventionNames":["Drug: Low dose Aspirin , Vitamin D","Drug: Aspirin Placebo, Vitamin D"]},{"label":"Aspirin placebo, Vitamin D placebo","type":"EXPERIMENTAL","interventionNames":["Drug: Aspirin placebo, Vitamin D placebo"]}],"interventions":[{"name":"High dose Aspirin & Vitamin D","otherNames":["Aspirin - acetylsalicylic acid","Vitamin D - Vigantol® Oil"]},{"name":"High dose Aspirin, Vitamin D placebo","otherNames":["Aspirin - acetylsalicylic acid","Vitamin D placebo - Miglyol®812 Oil"]},{"name":"Low dose Aspirin , Vitamin D","otherNames":["Aspirin - acetylsalicylic acid","Vitamin D - Vigantol® Oil"]},{"name":"Low dose Aspirin, Vitamin D placebo","otherNames":["Aspirin - acetylsalicylic acid","Vitamin D placebo - Miglyol®812 Oil"]},{"name":"Aspirin Placebo, Vitamin D","otherNames":["Vitamin D - Vigantol® Oil"]},{"name":"Aspirin placebo, Vitamin D placebo","otherNames":["Aspirin Placebo, Vitamin D","Vitamin D placebo - Miglyol®812 Oil"]}],"eligibilityModule":{"eligibilityCriteria":"1. Male subjects aged 16 years or over with an estimated life expectancy of more than three years\n2. Willing and able to provide written informed consent\n3. Corrected serum calcium ≤ 2.65mmol/l\n4. No previous treatment for prostate cancer (including surgery, hormone therapy, radiotherapy, cryotherapy)\n5. Must have undergone a multi-parametric MRI of the prostate, deemed assessable by the local radiologist, and any lesions seen must have undergone targeted biopsy, (transrectal or transperineal) within 12 months of study registration.\n6. Histologically confirmed prostate cancer\\* following prostate biopsy (including at least 10 cores of prostate tissue) in men opting for Active Surveillance as their primary cancer therapy.\n\n   * PROVENT Prostate Cancer Criteria. All must be met for Inclusion:\n\n     * Gleason score 6 or 7 (Gleason 3+3 or 3+4)\n     * Clinical and radiological stage \\<T3\n     * Serum Prostate Specific Antigen (PSA) ≤15.0 ng/ml\n     * Less than 10mm of cancer in a single core\n\nExclusion Criteria:\n\n1. Previously treated prostate cancer (including radiotherapy, hormone therapy, brachytherapy or surgery)\n2. Currently enrolled, or has been a participant within the last 30 days, in any other investigational drug or device study.\n3. Current daily use of aspirin or NSAIDs; or daily dietary supplements/medication containing more than 400 IU (10 micrograms per day) Vitamin D; or chronic use (defined as \\> 6 months continuous daily use) of either aspirin or \\>400IU Vitamin D within two years of study enrolment\n4. Current or previous use of 5-α reductase inhibitors such as finasteride or dutasteride\n5. Not willing to comply with the procedural requirements of this protocol including repeat prostate biopsies\n6. Known allergy/sensitivity to or intolerance of aspirin, other salicylates or NSAIDs e.g. ibuprofen/ naproxen\n7. Prior history of gastro-intestinal bleeding or ulceration, severe dyspepsia or inflammatory bowel disease\n8. Haemophilia or other bleeding diatheses\n9. Prior history of renal stone disease\n10. Chronic renal disease (≥stage 4)\n11. Known hypercalcaemia (corrected serum calcium \\>2.65 mmol/l) or untreated hyperparathyroidism\n12. Any bowel condition that would make repeat transrectal biopsy hazardous or difficult to perform e.g. recto-urethral fistula, or prior bowel surgery such as abdomino-perineal resection.\n13. Any malignancy (other than non-melanoma skin cancer) that has not been in complete remission for five years\n14. Any serious co-existent medical condition that would make repeat prostate biopsy hazardous e.g. anti-coagulation requiring continuous administration\n15. Severe Asthma\n16. G6PD ( glucose-6-phosphate dehydrogenase) deficiency\n17. Pre-existing macular degeneration\n18. All contraindications to aspirin and Vitamin D3 (e.g. Sarcoidosis), including concomitant therapy with any medication that may interact with aspirin or Vitamin D3 (see section 4.10)\n19. Tuberculosis\n20. Regular consumption of alcohol units greater than the recommended daily limit of 3-4 units per day (men)","healthyVolunteers":false,"sex":"MALE","minimumAge":"16 Years","maximumAge":"100 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Rate of Patient Recruitment to a Randomised Chemoprevention Study in Men Enrolled on an Active Surveillance Programme for Prostate Cancer. Number Accrued Per Month.","description":"The proportion of eligible patients that join the trial over the 12-month trial recruitment period.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"16","spread":null},{"groupId":"OG002","value":"19","spread":null},{"groupId":"OG003","value":"18","spread":null},{"groupId":"OG004","value":"16","spread":null},{"groupId":"OG005","value":"18","spread":null}]}]}]},{"type":"SECONDARY","title":"Response to Treatment as Determined by Serial Multi-parametric Magnetic Resonance Imaging (MRI) of the Prostate. New Lesion Present or Existing Lesion + or - in Size.","description":"Radiological progression was defined as 'development of a Prostate Imaging-Reporting and Data System (PI-RADS) 4/5 lesion (17) on mpMRI, where no lesion was identified before, 33% volume increase in the size of the lesion, or radiological upstaging to T3 or above based on local site reports.' Absence of these features represented radiologically stable disease.\n\nLesion on multi-parametric imaging where no MRI lesion at screening. An MRI scan shows a screening + or - in volume by \\> 33%, or an upgrading of MRI stage of disease to ≥3.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"5","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"3","spread":null},{"groupId":"OG005","value":"2","spread":null}]},{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"2","spread":null},{"groupId":"OG003","value":"4","spread":null},{"groupId":"OG004","value":"6","spread":null},{"groupId":"OG005","value":"6","spread":null}]},{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"1","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Biochemical (PSA) Disease Progression","description":"50% increase in serum Prostate Specific Antigen at 12 months from baseline.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"1","spread":null}]},{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"10","spread":null},{"groupId":"OG002","value":"10","spread":null},{"groupId":"OG003","value":"10","spread":null},{"groupId":"OG004","value":"10","spread":null},{"groupId":"OG005","value":"13","spread":null}]},{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"2","spread":null},{"groupId":"OG005","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Histological Disease Progression","description":"Histological disease progression will be defined as an increase in Gleason scores from: Gleason 3+3 to Gleason score 7 or higher Gleason 3+4 (score 7) to 4+3 (score 7) or Gleason 4+3 to a higher score\n\nOr a 50% increase in maximum cancer core length (MCCL)","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"7","spread":null},{"groupId":"OG002","value":"5","spread":null},{"groupId":"OG003","value":"2","spread":null},{"groupId":"OG004","value":"3","spread":null},{"groupId":"OG005","value":"6","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients With Adverse With Toxicity, Allergy or Symptoms From Aspirin or Vitamin D","description":"Aspirin toxicity: Haemorrhagic stroke, anaphylaxis following administration, gastrointestinal bleeding requiring intervention (both medical and surgical)\n\nVitamin D3 toxicity: Hypercalcaemia, Anaphylaxis","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"1","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"2","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"16","spread":null},{"groupId":"OG002","value":"17","spread":null},{"groupId":"OG003","value":"18","spread":null},{"groupId":"OG004","value":"16","spread":null},{"groupId":"OG005","value":"17","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":17},"commonTop":["Cold","Headache","Diarrhoea","Nose Bleed","Sore Throat"]}}}